A Phase 3 interventional study of Abatacept and Methotrexate in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-08.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 14th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 34th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 3, and was the 16th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate the clinical efficacy of abatacept (body-weight tiered dose approximating 10 mg/kg) compared with placebo on a background of methotrexate after 6 months (Day 169) of treatment in Korean patients with active rheumatoid arthritis and an inadequate clinical response to methotrexate
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: Abatacept · Drug: Methotrexate
(standard of care)
Drug: Methotrexate · Drug: Placebo
Open-label extension phase
Drug: Abatacept · Drug: Methotrexate
Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
Also known as: Orencia, BMS-188667
Tablets, Oral, ≥ 15 mg, weekly, 6 months
IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
Solution, intravenous, 10 mg/kg, every 28 days
Also known as: Orencia, BMS-188667
Tablets, oral, 15 mg weekly to be adjusted according to patient condition
Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20)
The ACR 20 is based on 20% improvement (compared with baseline values) in tender and swollen joint counts and on 20% improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.
Time frame: At Day 169
Long-term Extension (LTE) (Open-Label) Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuatons Due to SAEs, Adverse Events (AEs), Related AEs, and Discontinuations Due to AEs
AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: Day 169 to up to 56 days post the last dose (Day 1485) in the LTE period
Percentage of Participants With American College of Rheumatology (ACR) ACR50 and ACR70 Response at Day 169
The ACR defines ACR 50 and ACR70 response as a 50% or 70% improvement (compared with baseline values) in tender and swollen joint counts and 50% or 70% improvement in 3 of the remaining 5 core set measures (patient global assessment of pain, patient global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function) and 1 acute phase reactant value (C-reactive protein).
Time frame: At Day 169
Percentage of Participants With at Least 20%, 50%, or 70% Improvement From Baseline in American College of Rheumatology (ACR) Core Components
The ACR defines improvement in core components as 20%, 50%, or 70% improvement in tender and swollen joint counts and 3 of the remaining core components: patient global assessment of disease activity, physician global assessment of disease activity, patient assessment of pain, patient self-assessed disability (Health Assessment Questionnaire Disability Index \[HAQ-DI\]), and levels of 1 acute phase reactant (C-reactive protein levels or erythrocyte sedimentation rate.) The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning; scale=0 (no disability) to 3 (completely disabled); total possible score=24. The higher the score, the greater the disability.
Time frame: From Baseline to Day 169
Change From Baseline in Disease Activity Scores (DAS) Based on C-reactive Protein (DAS 28 [CRP]) Levels or Erythrocyte Sedimentation Rate (DAS 28[ESR])
Adjusted mean change from baseline. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission). CRP or ESR give estimations of DAS28 values on a group level. Change from Baseline=Postbaseline - Baseline value.
Time frame: From Baseline to Days 169 and 1485
Change From Baseline to Day 169 in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
Adjusted mean change from baseline. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.
Time frame: From Baseline to Day 169
Change From Baseline to Day 169 in Analysis of Short-Form 36 (SF-36) Health Survey Questionnaire Domains
Adjusted mean change from baseline. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life and comprised of 8 domains( including 4 physical and 4 mental subscales) used to derive the physical and mental component summary scores. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Change from baseline=postbaseline - baseline value.
Time frame: From Baseline to Day 169
Percentage of Participants Experiencing Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), Related SAEs and AEs, and Discontinuations Due to SAEs and AEs During the Double-Blind Period
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: Throughout double-blind study period (up to Day 169); table includes data up to 56 days past double-blind period or start of the open-label period, whichever occurred first.
Abatacept Pharmacokinetic (PK) Parameters: Time to Maximum Concentration (Tmax) and Half-Life of Elimination (T-Half)
Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Tmax = the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. T-Half = the biological half-life or elimination half life of a substance is the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity.
Time frame: At the end of infusion and 2 to 4 hours after the start of infusion on Day 85, at anytime between Day 92 and 96, and pre-dose on Day 113
Abatacept Pharmacokinetic (PK) Parameters - Maximum Concentration (Cmax)
Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Maximum Concentration (Cmax)= the maximum plasma concentration of the drug.
Time frame: At the end of infusion and 2 to 4 hours after the start of the infusion on Day 85, at anytime between Day 92 and 96, and pre-dose on Day 113
Abatacept Pharmacokinetic (PK) Parameters - Area Under the Curve (AUC)
Area Under the Plasma Concentration-Time Curve (AUC), a measure of drug absorption, in a dosing interval of 28 days from Day 85 to Day 113. Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.
Time frame: At the end of infusion, 2 to 4 hours after the start of infusion on Day 85, anytime between Day 92 and 96, and predose on Day 113
Abatacept Pharmacokinetic (PK) Parameters: Total Body Clearance (CLT)
Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Clearance is a pharmacokinetic parameter that describes how quickly drugs are eliminated, metabolized or distributed throughout the body.
Time frame: Day 29, every 28 days until Day 141
Abatacept Pharmacokinetic (PK) Parameters: Volume at Steady State (VSS)
The volume of distribution of drug at steady state (VSS). Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.
Time frame: At the end of infusion, 2 to 4 hours after the start of infusion on Day 85, anytime between Day 92 and 96, and predose on Day 113
Summary Statistics of Minimum Observed Serum Concentration (Cmin) for Abatacept
Minimum concentration (Cmin) of Abatacept 500 mg and 750 mg at given time points
Time frame: At the end of infusion and 2 to 4 hours after the start of the infusion on Day 85
Immunogenicity of Abatacept- Number of Participants With Reactivity Toward CTLA4-IG and CTLA4-T at Day 169
Immunogenicity was determined by measuring adult subject sera for reactivity against the whole Abatacept molecule (CTLA4Ig) and CTLA4-T (CTLA4 without the Ig regions).
Time frame: Day 169
Change From Baseline in Surrogate Marker Erythrocyte Sedimentation Rate (ESR) at Day 169
Mean change in surrogate marker mean ESR. A surrogate marker is an indirect measurement of effectiveness. Change from Baseline = postbaseline - baseline value.
Time frame: From Baseline to Day 169
Change From Baseline in Surrogate Marker Rheumatoid Factor (RF) at Day 169
Mean change in RF. A surrogate marker is an indirect measurement of effectiveness. Mean change from Baseline = postbaseline - baseline value.
Time frame: Baseline, Day 169
LTE Period: Overall Number of Participants With Positive Results of Immunogenicity Samples
Positive antibody titers were identified by validated enzyme-linked immunosorbent assay results. On-treatment samples were obtained during the LTE period, and posttreatment samples were following the last infusion of study medication.
Time frame: Days 169, at 6-month intervals on-treatment, and at Days 28, 56, and 85 after the last infusion of study medication in the LTE period
Percentage of Participants Achieving ACR20, ACR50, and ACR70 Over Time
The ACR 20, ACR50, and ACR70 are based on 20%, 50% and 70% improvement, respectively, (compared with baseline values) in tender and swollen joint counts and on 20%, 50% and 70%, respectively, improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.
Time frame: Days 15 through 1569
Percentage of Participants With Physical Function Response as Assessed Using the Health Assessment Questionnaire Disability Index (HAQ-DI)
Improvement is measured by an improved response of at least 0.3 units from baseline on the HAQ-DI score. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.
Time frame: At Day 1485
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.
Time frame: Day 1485
Changes From Baseline in Short-Form 36 (SF-36) Physical and Mental Health Summaries
The SF-36 is a 36-item questionnaire used to measure Quality of Life over 8 physically and emotionally based areas: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Answers to each question correspond to a precoded numeric value. An aggregate percentage score is reached for each of the 8 sections and is based on answers to questions. The mean average is worked out for each section. Scores range from 0% (lowest level of functioning) to 100% (highest level of functioning, with higher score indicated increasing levels of functioning.
Time frame: At Day 1485
Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and With EULAR-defined Remission
EULAR defines LDAS as a disease activity score as measured by c-reactive protein (DAS28-CRP) ≤3.2 and remission as DAS28-CRP \<2.6
Time frame: At Days 169 and 1485
Changes From Baseline in the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) Scores
The SDAI is the sum of 5 parameters: Tender joint (TJC) and swollen joint(SJC)counts, based on a 28-joint assessment; patient global (PtGA)and physician global assessments (PGA), assessed on 0-10 cm visual analog scale (VAS), on which higher scores=greater affection due to disease activity DA); and C-reactive protein level. SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low DA, \>11 to 26=moderate DA, and \>26=high DA. SJC is assessed at each visit, with no swelling=0, swelling=1. TJC is assessed through identification of joints painful under pressure or to passive motion at each visit, with no tenderness=0, tenderness=1. Higher score=greater affection due to DA. CDAI is sum of 4 parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score=0-76. CDAI \<=2.8 indicates disease remission, \>2.8 to 10=low DA, \>10 to 22=moderate DA, and \>22=high DA.
Time frame: At Days 169 and 1569
Percentage of Participants With Low Disease Activity Score (LDAS) or Who Are in Remission
LDAS is defined as a Disease Activity Score C-reactive protein (DAS28-CRP) level \<=3.2. Remission is defined as a DAS28-CRP level \<2.6.
Time frame: At Days 169, 337, 729, 1149, and 1485
Change From Baseline in Levels of C-reactive Protein (CRP)
Time frame: Days 169 to 1569
Change From Baseline in Erythrocyte Sedimentation Rate
Time frame: Days 169 to 1569
| Milestone | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Started | 56 | 57 |
| Treated (baseline) population | 55 | 57 |
| Completed | 53 | 52 |
| Not completed | 3 | 5 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Never treated | 1 | 0 |
| Milestone | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Started | 105 | 0 |
| Completed | 87 | 0 |
| Not completed | 18 | 0 |
| Withdrew: Adverse event | 10 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Poor compliance/noncompliance | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
The ACR 20 is based on 20% improvement (compared with baseline values) in tender and swollen joint counts and on 20% improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.
| percentage of participants | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20) | 65.5 | 42.1 |
The ACR defines ACR 50 and ACR70 response as a 50% or 70% improvement (compared with baseline values) in tender and swollen joint counts and 50% or 70% improvement in 3 of the remaining 5 core set measures (patient global assessment of pain, patient global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function) and 1 acute phase reactant value (C-reactive protein).
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| ACR 50 | 32.7 | 15.8 |
| ACR 70 | 14.5 | 7.0 |
The ACR defines improvement in core components as 20%, 50%, or 70% improvement in tender and swollen joint counts and 3 of the remaining core components: patient global assessment of disease activity, physician global assessment of disease activity, patient assessment of pain, patient self-assessed disability (Health Assessment Questionnaire Disability Index \[HAQ-DI\]), and levels of 1 acute phase reactant (C-reactive protein levels or erythrocyte sedimentation rate.) The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning; scale=0 (no disability) to 3 (completely disabled); total possible score=24. The higher the score, the greater the disability.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Tender Joints ≥ 20% improvement | 81.1 | 76.9 |
| Tender Joints ≥ 50% improvement | 66.0 | 50.0 |
| Tender Joints ≥ 70% improvement | 49.1 | 23.1 |
| Swollen Joints ≥ 20% improvement | 92.5 | 76.9 |
| Swollen Joints ≥ 50% improvement | 77.4 | 57.7 |
| Swollen Joints ≥ 70% improvement | 60.4 | 40.4 |
| Patient Pain Assessment ≥ 20% improvement | 73.6 | 53.9 |
| Patient Pain Assessment ≥ 50% improvement | 47.2 | 23.1 |
| Patient Pain Assessment ≥ 70% improvement | 28.3 | 11.5 |
| HAQ-DI ≥ 20% improvement | 67.9 | 44.2 |
| HAQ-DI ≥ 50% improvement | 32.1 | 23.1 |
| HAQ-DI ≥ 70% improvement | 20.8 | 5.8 |
| Patient Global Assessment ≥ 20% improvement | 66.0 | 53.9 |
| Patient Global Assessment ≥ 50% improvement | 39.6 | 21.2 |
| Patient Global Assessment ≥ 70% improvement | 26.4 | 11.5 |
| Physician Global Assessment ≥ 20% improvement | 86.8 | 71.2 |
| Physician Global Assessment ≥ 50% improvement | 60.4 | 40.4 |
| Physician Global Assessment ≥ 70% improvement | 30.2 | 19.2 |
| C-reactive Protein ≥ 20% improvement | 83.0 | 61.5 |
| C-reactive Protein ≥ 50% improvement | 75.5 | 53.9 |
| C-reactive Protein ≥ 70% improvement | 64.2 | 28.9 |
Adjusted mean change from baseline. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission). CRP or ESR give estimations of DAS28 values on a group level. Change from Baseline=Postbaseline - Baseline value.
| Units on a scale | Abatacept | Placebo |
|---|---|---|
| Day 169: DAS28 (CRP) | -2.12 ± 0.17 | -1.21 ± 0.17 |
| Day 169: DAS28 (ESR) | -2.22 ± 0.17 | -1.15 ± 0.16 |
| Day 1485: DAS28 (CRP) (n=31, 35) | -2.97 ± 0.23 | -3.13 ± 0.22 |
| Day 1485: DAS28 (ESR) (NA) | NA ± NA | NA ± NA |
Adjusted mean change from baseline. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.
| Units on a scale | Abatacept | Placebo |
|---|---|---|
| HAQ Disability Index | -0.53 ± 0.07 | -0.24 ± 0.07 |
| Dressing and Grooming | -0.58 ± 0.09 | -0.37 ± 0.09 |
| Arising | -0.58 ± 0.10 | -0.36 ± 0.10 |
| Eating | -0.52 ± 0.09 | -0.13 ± 0.09 |
| Walking | -0.54 ± 0.10 | -0.23 ± 0.10 |
| Hygiene | -0.37 ± 0.09 | -0.21 ± 0.09 |
| Reaching | -0.34 ± 0.11 | -0.11 ± 0.10 |
| Gripping | -0.67 ± 0.11 | -0.36 ± 0.11 |
| Activities | -0.56 ± 0.10 | -0.25 ± 0.10 |
Adjusted mean change from baseline. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life and comprised of 8 domains( including 4 physical and 4 mental subscales) used to derive the physical and mental component summary scores. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Change from baseline=postbaseline - baseline value.
| Units on a scale | Abatacept | Placebo |
|---|---|---|
| Physical Component Summary | 6.52 ± 1.05 | 2.16 ± 1.06 |
| Mental Component Summary | 8.18 ± 1.37 | 4.36 ± 1.38 |
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Deaths | 0 | 1.8 |
| SAEs | 3.6 | 5.3 |
| Related SAEs | 0 | 1.8 |
| Discontinued due to SAEs | 0 | 1.8 |
| AEs | 70.9 | 70.2 |
| Related AEs | 12.7 | 15.8 |
| Discontinued due to AEs | 0 | 1.8 |
Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Tmax = the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. T-Half = the biological half-life or elimination half life of a substance is the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity.
| Hours | Abatacept 500 mg | Abatacept 750 mg | Abatacept 500 mg and 750 mg |
|---|---|---|---|
| Tmax | 1.385 ± 1.0607 | 1.193 ± 0.9956 | 1.325 ± 1.0351 |
| T-Half | 183.583 ± 35.2606 | 172.451 ± 28.7270 | 180.078 ± 33.4795 |
Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Maximum Concentration (Cmax)= the maximum plasma concentration of the drug.
| μg/mL | Abatacept 500 mg | Abatacept 750 mg | Abatacept 500 mg and 750 mg |
|---|---|---|---|
| Abatacept Pharmacokinetic (PK) Parameters - Maximum Concentration (Cmax) | 241.972 ± 41.7191 | 312.591 ± 63.3026 | 264.204 ± 59.0589 |
Area Under the Plasma Concentration-Time Curve (AUC), a measure of drug absorption, in a dosing interval of 28 days from Day 85 to Day 113. Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.
| μg.h/mL | Abatacept 500 mg | Abatacept 750 mg | Abatacept 500 mg and 750 mg |
|---|---|---|---|
| Abatacept Pharmacokinetic (PK) Parameters - Area Under the Curve (AUC) | 38940.063 ± 9731.0561 | 48283.479 ± 10283.2572 | 41881.508 ± 10743.8152 |
Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Clearance is a pharmacokinetic parameter that describes how quickly drugs are eliminated, metabolized or distributed throughout the body.
| mL/h/kg | Abatacept 500 mg | Abatacept 750 mg | Abatacept 500 mg and 750 mg |
|---|---|---|---|
| Abatacept Pharmacokinetic (PK) Parameters: Total Body Clearance (CLT) | 0.269 ± 0.0730 | 0.240 ± 0.0460 | 0.260 ± 0.0666 |
The volume of distribution of drug at steady state (VSS). Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.
| L/kg | Abatacept 500 mg | Abatacept 750 mg | Abatacept 500 mg and 750 mg |
|---|---|---|---|
| Abatacept Pharmacokinetic (PK) Parameters: Volume at Steady State (VSS) | 0.064 ± 0.0165 | 0.055 ± 0.0142 | 0.061 ± 0.0162 |
Minimum concentration (Cmin) of Abatacept 500 mg and 750 mg at given time points
| μg/mL | Abatacept 500 mg | Abatacept 750 mg | Abatacept 500 mg and 750 mg |
|---|---|---|---|
| Day 29 | 37.76 ± 10.971 | 52.19 ± 19.619 | 42.30 ± 15.611 |
| Day 57 | 19.96 ± 11.337 | 24.42 ± 7.697 | 21.31 ± 10.504 |
| Day 85 | 17.45 ± 7.442 | 20.83 ± 10.749 | 18.52 ± 8.661 |
| Day 113 | 17.51 ± 6.858 | 22.06 ± 9.365 | 18.94 ± 7.936 |
Immunogenicity was determined by measuring adult subject sera for reactivity against the whole Abatacept molecule (CTLA4Ig) and CTLA4-T (CTLA4 without the Ig regions).
| participants | Abatacept + Background Methotrexate |
|---|---|
| Reactivity toward CTLA4-T | 0 |
| Reactivity toward CTLA4Ig | 0 |
Mean change in surrogate marker mean ESR. A surrogate marker is an indirect measurement of effectiveness. Change from Baseline = postbaseline - baseline value.
| mm/h | Abatacept | Placebo |
|---|---|---|
| Change From Baseline in Surrogate Marker Erythrocyte Sedimentation Rate (ESR) at Day 169 | -30.0 ± 2.86 | -4.44 ± 3.87 |
Mean change in RF. A surrogate marker is an indirect measurement of effectiveness. Mean change from Baseline = postbaseline - baseline value.
| IU/mL | Abatacept | Placebo |
|---|---|---|
| Change From Baseline in Surrogate Marker Rheumatoid Factor (RF) at Day 169 | -54.1 ± 20.52 | -12.1 ± 14.38 |
AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Participants | All Treated |
|---|---|
| Deaths | 1 |
| SAEs | 41 |
| Related SAEs | 10 |
| Discontinuations due to SAEs | 8 |
| AEs | 100 |
| Related AEs | 45 |
| Discontinuations due to AEs | 10 |
Positive antibody titers were identified by validated enzyme-linked immunosorbent assay results. On-treatment samples were obtained during the LTE period, and posttreatment samples were following the last infusion of study medication.
| Participants | All Treated |
|---|---|
| Overall | 14 |
| On-treatment | 9 |
| Posttreatment | 11 |
The ACR 20, ACR50, and ACR70 are based on 20%, 50% and 70% improvement, respectively, (compared with baseline values) in tender and swollen joint counts and on 20%, 50% and 70%, respectively, improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.
| Percentage of participants | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Day 15 ACR20 | 13.2 (4.1 to 22.3) | 11.5 (2.9 to 20.2) |
| Day 15 ACR50 | 1.9 (0.0 to 10.1) | 3.8 (0.5 to 13.2) |
| Day 15 ACR70 | 0 (NA to NA) | 0 (NA to NA) |
| Day 29 ACR20 | 24.5 (12.9 to 36.1) | 21.2 (10.1 to 32.3) |
| Day 29 ACR50 | 1.9 (0.0 to 10.0) | 7.7 (2.1 to 18.5) |
| Day 29 ACR70 | 1.9 (0.0 to 10.0) | 3.8 (0.5 to 13.2) |
| Day 57 ACR20 (n=52, 52) | 51.9 (38.3 to 65.5) | 23.1 (11.6 to 34.5) |
| Day 57 ACR50 (n=52, 52) | 5.8 (1.2 to 15.9) | 7.7 (2.1 to 18.5) |
| Day 57 ACR70 (n=52, 52) | 1.9 (0.0 to 10.3) | 5.8 (1.2 to 15.9) |
| Day 85 ACR20 | 58.5 (45.2 to 71.8) | 36.5 (23.5 to 49.6) |
| Day 85 ACR50 | 17.0 (6.9 to 27.1) | 9.6 (1.6 to 17.6) |
| Day 85 ACR70 | 5.7 (1.2 to 15.7) | 7.7 (2.1 to 18.5) |
| Day 113 ACR20 | 64.2 (51.2 to 77.1) | 48.1 (34.5 to 61.7) |
| Day 113 ACR50 | 30.2 (17.8 to 42.5) | 11.5 (2.9 to 20.2) |
| Day 113 ACR70 | 3.8 (0.5 to 13.0) | 7.7 (2.1 to 18.5) |
| Day 141 ACR20 | 66.0 (53.3 to 78.8) | 53.8 (40.3 to 67.4) |
| Day 141 ACR50 | 30.2 (17.8 to 42.5) | 11.5 (2.9 to 20.2) |
| Day 141 ACR70 | 15.1 (5.5 to 24.7) | 7.7 (2.1 to 18.5) |
| Day 169 ACR20 | 67.9 (55.4 to 80.5) | 46.2 (32.6 to 59.7) |
| Day 169 ACR50 | 34.0 (21.2 to 46.7) | 17.3 (7.0 to 27.6) |
| Day 169 ACR70 | 15.1 (5.5 to 24.7) | 7.7 (2.1 to 18.5) |
| Day 197 ACR20 (n=53, 50) | 75.5 (63.9 to 87.1) | 60.0 (46.4 to 73.6) |
| Day 197 ACR50 (n=53, 51) | 45.3 (31.9 to 58.7) | 37.3 (24.0 to 50.5) |
| Day 197 ACR70 (n=53, 51) | 22.6 (11.4 to 33.9) | 11.8 (2.9 to 20.6) |
| Day 225 ACR20 | 75.5 (63.9 to 87.1) | 65.4 (52.5 to 78.3) |
| Day 225 ACR50 | 49.1 (35.6 to 62.5) | 32.7 (19.9 to 45.4) |
| Day 225 ACR70 | 22.6 (11.4 to 83.9) | 13.5 (4.2 to 22.7) |
| Day 253 ACR20 (n=52, 51) | 71.2 (58.8 to 83.5) | 64.7 (51.6 to 77.8) |
| Day 253 ACR50 (n=52, 51) | 44.2 (30.7 to 57.7) | 35.3 (22.2 to 48.4) |
| Day 253 ACR70 (n=52, 51) | 21.2 (10.1 to 32.3) | 13.7 (4.3 to 23.2) |
| Day 337 ACR20 (n=52, 51) | 78.8 (67.7 to 89.9) | 62.7 (49.5 to 76.0) |
| Day 337 ACR50 (n=52, 51) | 48.1 (34.5 to 61.7) | 43.1 (29.5 to 56.7) |
| Day 337 ACR70 (n=52, 51) | 30.8 (18.2 to 43.3) | 17.6 (7.2 to 28.1) |
| Day 421 ACR20 (n=51, 51) | 84.3 (74.3 to 94.3) | 78.4 (67.1 to 89.7) |
| Day 421 ACR50 (n=51, 51) | 49.0 (35.3 to 62.7) | 56.9 (43.3 to 70.5) |
| Day 421 ACR70 (n=51, 51) | 29.4 (16.9 to 41.9) | 31.4 (18.6 to 44.1) |
| Day 505 ACR20 (n=50, 51) | 88.0 (79.0 to 97.0) | 84.3 (74.3 to 94.3) |
| Day 505 ACR50 (n=50, 51) | 62.0 (48.5 to 75.5) | 56.9 (43.3 to 70.5) |
| Day 505 ACR70 (n=50, 51) | 40.0 (26.4 to 53.6) | 25.5 (13.5 to 37.5) |
| Day 561 ACR20 (n=50, 50) | 88.0 (79.0 to 97.0) | 86.0 (76.4 to 95.6) |
| Day 561 ACR50 (n=50, 50) | 64.0 (50.7 to 77.3) | 60.0 (46.4 to 73.6) |
| Day 561 ACR70 (n=50, 50) | 38.0 (24.5 to 51.5) | 32.0 (19.1 to 44.9) |
| Day 645 ACR20 (n=50, 50) | 86.0 (76.4 to 95.6) | 82.0 (71.4 to 92.6) |
| Day 645 ACR50 (n=50, 50) | 54.0 (40.2 to 67.8) | 56.0 (42.2 to 69.8) |
| Day 645 ACR70 (n=50, 50) | 38.0 (24.5 to 51.5) | 34.0 (20.9 to 47.1) |
| Day 729 ACR20 (n=49, 50) | 83.7 (73.3 to 94.0) | 74.0 (61.8 to 86.2) |
| Day 729 ACR50 (n=49, 50) | 63.3 (49.8 to 76.8) | 54.0 (40.2 to 67.8) |
| Day 729 ACR70 (n=49, 50) | 34.7 (21.4 to 48.0) | 32.0 (19.1 to 44.9) |
| Day 813 ACR20 (n=48, 49) | 91.7 (83.8 to 99.5) | 79.6 (68.3 to 90.9) |
| Day 813 ACR50 (n=48, 49) | 58.3 (44.4 to 72.3) | 59.2 (45.4 to 72.9) |
| Day 813 ACR70 (n=48, 49) | 41.7 (27.7 to 55.6) | 34.7 (21.4 to 48.0) |
| Day 897 ACR20 (n=46, 49) | 80.4 (69.0 to 91.9) | 79.6 (68.3 to 90.9) |
| Day 897 ACR50 (n=46, 49) | 56.5 (42.2 to 70.8) | 53.1 (39.1 to 67.0) |
| Day 897 ACR70 (n=46, 49) | 39.1 (25.0 to 53.2) | 34.7 (21.4 to 48.0) |
| Day 981 ACR20 (n=44, 48) | 84.1 (73.3 to 94.9) | 79.2 (67.7 to 90.7) |
| Day 981 ACR50 (n=44, 48) | 61.4 (47.0 to 75.8) | 60.4 (46.6 to 74.3) |
| Day 981 ACR70 (n=43, 48) | 34.9 (20.6 to 49.1) | 41.7 (27.7 to 55.6) |
| Day 1065 ACR20 (n=45, 48) | 80.0 (68.3 to 91.7) | 79.2 (67.7 to 90.7) |
| Day 1065 ACR50 (n=45, 48) | 64.4 (50.5 to 78.4) | 60.4 (46.6 to 74.3) |
| Day 1065 ACR70 (n=45, 48) | 42.2 (27.8 to 56.7) | 43.8 (29.7 to 57.8) |
| Day 1149 ACR20 (n=45, 48) | 84.4 (73.9 to 95.0) | 75.0 (62.8 to 87.2) |
| Day 1149 ACR50 (n=45, 48) | 55.6 (41.0 to 70.1) | 62.5 (48.8 to 76.2) |
| Day 1149 ACR70 (n=45, 48) | 35.6 (21.6 to 49.5) | 43.8 (29.7 to 57.8) |
| Day1233 ACR20 (n=44, 48) | 84.1 (73.3 to 94.9) | 79.2 (67.7 to 90.7) |
| Day1233 ACR50 (n=44, 48) | 63.6 (49.4 to 77.9) | 52.1 (38.0 to 66.2) |
| Day1233 ACR70 (n=44, 48) | 43.2 (28.5 to 57.8) | 41.7 (27.7 to 55.6) |
| Day 1317 ACR20 (n=44, 47) | 90.9 (82.4 to 99.4) | 76.6 (64.5 to 88.7) |
| Day 1317 ACR50 (n=44, 47) | 63.6 (49.4 to 77.9) | 53.2 (38.9 to 67.5) |
| Day 1317 ACR70 (n=44, 47) | 40.9 (26.4 to 55.4) | 36.2 (22.4 to 49.9) |
| Day 1401 ACR20 (n=41, 43) | 90.2 (81.2 to 99.3) | 81.4 (69.8 to 93.0) |
| Day 1401 ACR50 (n=41, 43) | 68.3 (54.0 to 82.5) | 51.2 (36.2 to 66.1) |
| Day 1401 ACR70 (n=41, 43) | 39.0 (24.1 to 54.0) | 39.5 (24.9 to 54.1) |
| Day 1485 ACR20 (n=31, 35) | 83.9 (70.9 to 96.8) | 85.7 (74.1 to 97.3) |
| Day 1485 ACR50 (n=31, 35) | 67.7 (51.3 to 84.2) | 62.9 (46.8 to 78.9) |
| Day 1485 ACR70 (n=31, 35) | 38.7 (21.6 to 55.9) | 45.7 (29.2 to 62.2) |
| Day 1569 ACR20 (n=20, 18) | 100.0 (100.0 to 100.0) | 88.9 (74.4 to 100.0) |
| Day 1569 ACR50 (n=20, 18) | 80.0 (62.5 to 97.5) | 72.2 (51.5 to 92.9) |
| Day 1569 ACR70 (n=20, 18) | 30.0 (9.9 to 50.1) | 44.4 (21.5 to 67.4) |
Improvement is measured by an improved response of at least 0.3 units from baseline on the HAQ-DI score. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.
| Percentage of participants | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Percentage of Participants With Physical Function Response as Assessed Using the Health Assessment Questionnaire Disability Index (HAQ-DI) | 77.4 | 60.0 |
The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.
| Units on a scale | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score | -0.76 ± 0.14 | -0.53 ± 0.11 |
The SF-36 is a 36-item questionnaire used to measure Quality of Life over 8 physically and emotionally based areas: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Answers to each question correspond to a precoded numeric value. An aggregate percentage score is reached for each of the 8 sections and is based on answers to questions. The mean average is worked out for each section. Scores range from 0% (lowest level of functioning) to 100% (highest level of functioning, with higher score indicated increasing levels of functioning.
| Units on a scale | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Physical component score | 10.34 ± 1.80 | 8.48 ± 1.57 |
| Mental component score | 7.93 ± 2.44 | 7.73 ± 2.34 |
EULAR defines LDAS as a disease activity score as measured by c-reactive protein (DAS28-CRP) ≤3.2 and remission as DAS28-CRP \<2.6
| Percentage of participants | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| EULAR-defined LDAS (Day 169) | 35.8 | 13.5 |
| EULAR-defined LDAS (Day 1485) (n=31, 35) | 61.3 | 68.6 |
| EULAR-defined remission (Day 169) | 24.5 | 9.6 |
| EULAR-defined remission(Day 1485) (n=31, 35) | 35.5 | 54.3 |
The SDAI is the sum of 5 parameters: Tender joint (TJC) and swollen joint(SJC)counts, based on a 28-joint assessment; patient global (PtGA)and physician global assessments (PGA), assessed on 0-10 cm visual analog scale (VAS), on which higher scores=greater affection due to disease activity DA); and C-reactive protein level. SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low DA, \>11 to 26=moderate DA, and \>26=high DA. SJC is assessed at each visit, with no swelling=0, swelling=1. TJC is assessed through identification of joints painful under pressure or to passive motion at each visit, with no tenderness=0, tenderness=1. Higher score=greater affection due to DA. CDAI is sum of 4 parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score=0-76. CDAI \<=2.8 indicates disease remission, \>2.8 to 10=low DA, \>10 to 22=moderate DA, and \>22=high DA.
| Units on a scale | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| SDAI score (Day 169) | -22.84 (-26.58 to -19.0) | -14.07 (-17.28 to -10.87) |
| SDAI score (Day 1569) (n=20, 18) | -29.74 (-34.06 to -25.43) | -29.20 (-33.70 to -24.70) |
| CDAI score (Day 169) | -20.99 (-24.52 to -17.46) | -13.49 (-16.42 to -10.56) |
| CDAI score (Day 1569) (n=20, 18) | -27.79 (-31.78 to -23.80) | -27.34 (-31.54 to -23.15) |
LDAS is defined as a Disease Activity Score C-reactive protein (DAS28-CRP) level \<=3.2. Remission is defined as a DAS28-CRP level \<2.6.
| Percentage of participants | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| LDAS (Day 169) | 35.8 (22.9 to 48.8) | 13.5 (4.2 to 22.7) |
| LDAS (Day 337) (n=52, 51) | 51.9 (38.3 to 65.5) | 35.3 (22.2 to 48.4) |
| LDAS (Day 729) (n=48, 50) | 62.5 (48.8 to 76.2) | 56.0 (42.2 to 69.8) |
| LDAS (Day 1149) (n=44,48) | 63.6 (49.4 to 77.9) | 60.4 (46.6 to 74.3) |
| LDAS (Day 1485) (n=31, 35) | 61.3 (44.1 to 78.4) | 68.6 (53.2 to 84.0) |
| Remission (Day 169) | 24.5 (12.9 to 36.1) | 9.6 (1.6 to 17.6) |
| Remission (Day 337) (n=52, 51) | 34.6 (21.7 to 47.5) | 23.5 (11.9 to 35.2) |
| Remission (Day 729) (n=48, 50) | 43.8 (29.7 to 57.8) | 38.0 (24.5 to 51.5) |
| Remission (Day 1149) (n=44,8) | 38.6 (24.2 to 53.0) | 50.0 (35.9 to 64.1) |
| Remission (Day 1485) (n=31, 35) | 35.5 (18.6 to 52.3) | 54.3 (37.8 to 70.8) |
| mg/dL | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Day 169 | -1.85 ± 0.29 | -0.58 ± 0.34 |
| Day 197 (n=53, 49) | -1.87 ± 0.28 | -1.23 ± 0.36 |
| Day 225 | -1.73 ± 0.51 | -1.62 ± 0.32 |
| Day 253 (n=52, 51) | -1.91 ± 0.31 | -1.52 ± 0.32 |
| Day 337 (n=52, 51) | -1.94 ± 0.30 | -1.67 ± 0.32 |
| Day 421 (n=51, 51) | -2.06 ± 0.26 | -1.77 ± 0.33 |
| Day 505 (n=50, 51) | -2.10 ± 0.28 | -1.75 ± 0.33 |
| Day 561 (n=50, 50) | -2.23 ± 0.27 | -1.68 ± 0.39 |
| Day 645 (n=50, 50) | -2.24 ± 0.28 | -1.88 ± 0.34 |
| Day 729 (n=49, 50) | -2.29 ± 0.28 | -1.63 ± 0.37 |
| Day 813 (n=48, 49) | -2.24 ± 0.29 | -1.81 ± 0.34 |
| Day 897 (n=46, 49) | -2.41 ± 0.30 | -1.76 ± 0.35 |
| Day 981 (n=44, 48) | -1.99 ± 0.33 | -1.99 ± 0.36 |
| Day 1065 (n=45, 48) | -2.06 ± 0.32 | -1.47 ± 0.40 |
| Day 1149 (n=45, 48) | -2.00 ± 0.34 | -1.86 ± 0.36 |
| Day 1233 (n=44, 48) | -1.96 ± 0.33 | 1.70 ± 0.37 |
| Day 1317 (n=44, 47) | -2.00 ± 0.35 | -1.81 ± 0.40 |
| Day 1401 (n=41, 43) | -1.93 ± 0.33 | -1.83 ± 0.40 |
| Day 1485 (n=31, 35) | -1.95 ± 0.47 | -1.86 ± 0.41 |
| Day 1569 (n=20, 18) | -2.43 ± 0.43 | -1.68 ± 0.42 |
| mm/h | Abatacept, 10 mg/kg | Placebo |
|---|---|---|
| Day 169 | -30.60 ± 2.93 | -7.12 ± 3.84 |
| Day 197 (n=53, 49) | -28.43 ± 3.27 | -15.14 ± 3.79 |
| Day 225 | -27.30 ± 3.09 | -20.27 ± 3.51 |
| Day 253 (n=52, 51) | -27.85 ± 3.24 | -20.78 ± 3.97 |
| Day 337 (n=52, 51) | -28.58 ± 3.35 | -23.86 ± 3.78 |
| Day 421 (n=51, 51) | -28.45 ± 3.34 | -24.94 ± 3.86 |
| Day 505 (n=50, 51) | -31.30 ± 3.46 | -24.69 ± 4.07 |
| Day 561 (n=50, 49) | -29.32 ± 3.63 | -24.90 ± 4.24 |
| Day 645 (n=50, 50) | -28.22 ± 3.74 | -27.38 ± 4.10 |
| Day 729 (n=49, 50) | -32.80 ± 3.70 | -23.04 ± 3.60 |
| Day 813 (n=48, 47) | -31.52 ± 3.95 | -22.91 ± 4.03 |
| Day 897 (n=46, 49) | -34.37 ± 4.13 | -18.22 ± 4.65 |
| Day 981 (n=44, 48) | -33.61 ± 3.68 | -21.54 ± 4.53 |
| Day 1065 (n=45, 47) | -31.53 ± 3.95 | -22.09 ± 4.37 |
| Day 1149 (n=45, 48) | -31.00 ± 4.59 | -20.29 ± 4.61 |
| Day 1233 (n=42, 48) | -30.93 ± 5.08 | -22.10 ± 4.70 |
| Day 1317 (n=43, 47) | -33.67 ± 4.45 | -21.89 ± 4.48 |
| Day 1401 (n=41, 43) | -32.41 ± 4.83 | -23.88 ± 4.91 |
| Day 1485 (n=31, 35) | -33.81 ± 6.96 | -25.69 ± 5.70 |
| Day 1569 (n=20, 18) | -46.80 ± 6.79 | -23.33 ± 5.85 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept 10 mg/kg | — | 2/55 (3.6%) | 27/55 (49.1%) |
| Placebo | — | 3/57 (5.3%) | 26/57 (45.6%) |
| Event | Abatacept 10 mg/kg | Placebo |
|---|---|---|
| ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications | 1/55 | 0/57 |
| LUMBAR SPINAL STENOSISMusculoskeletal and connective tissue disorders | 1/55 | 0/57 |
| ADRENAL CYSTEndocrine disorders | 0/55 | 1/57 |
| SEPSISInfections and infestations | 0/55 | 1/57 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 0/55 | 1/57 |
| PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders | 0/55 | 1/57 |
| INTERSTITIAL LUNG DISEASERespiratory, thoracic and mediastinal disorders | 0/55 | 1/57 |
| Event | Abatacept 10 mg/kg | Placebo |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 4/55 | 9/57 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/55 | 3/57 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 5/55 | 6/57 |
| WEIGHT INCREASEDInvestigations | 4/55 | 0/57 |
| HEADACHENervous system disorders | 3/55 | 3/57 |
| DYSPEPSIAGastrointestinal disorders | 3/55 | 2/57 |
| MOUTH ULCERATIONGastrointestinal disorders | 3/55 | 1/57 |
| EPIGASTRIC DISCOMFORTGastrointestinal disorders | 3/55 | 1/57 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/55 | 2/57 |
| PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders | 3/55 | 0/57 |
| Age Continuous(years) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 47.2 ± 12.2 | 49.9 ± 10.6 | 48.6 ± 11.4 |
| Sex: Female, Male(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Female | 47 | 49 | 96 |
| Male | 8 | 8 | 16 |
| weight(kilograms) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 56.5 ± 9.5 | 54.2 ± 7.5 | 55.3 ± 8.6 |
The record gives a start of Apr 2007, a primary completion of Jul 2008 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept